Menu
← Oncology Approval Tracker
FDA DECISION ·
Tecartus
brexucabtagene autoleucel · Kite Pharma
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory mantle cell lymphoma. FDA converted the accelerated indication to traditional approval.
LAMPGEN ANALYSIS
Why it matters
This completes the accelerated-approval pathway for the mantle cell lymphoma use of Tecartus. The decision is specific to that CAR-T indication.
What research teams should watch
Keep MCL evidence separate from the product’s other uses. Verify follow-up obligations, referral timelines and the practical constraints of CAR-T delivery.
PRIMARY RECORDS